Breaking News Instant updates and real-time market news.

OPHT

Ophthotech

$43.57

-2.56 (-5.55%)

, REGN

Regeneron

$402.82

0.8 (0.20%)

06:04
10/04/16
10/04
06:04
10/04/16
06:04

Ophthotech price target raised to $110 from $95 at JPMorgan

JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.

OPHT

Ophthotech

$43.57

-2.56 (-5.55%)

REGN

Regeneron

$402.82

0.8 (0.20%)

  • 30

    Oct

  • 29

    Mar

OPHT Ophthotech
$43.57

-2.56 (-5.55%)

04/27/16
LEHM
04/27/16
INITIATION
Target $85
LEHM
Overweight
Ophthotech initiated with an Overweight at Barclays
Barclays analyst Carter Gould started Ophthotech with an Overweight rating and $85 price target.
06/02/16
JPMS
06/02/16
UPGRADE
Target $84
JPMS
Overweight
Ophthotech upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Ophthotech to Overweight saying the Fovista phase 3 Lucentis combination studies reading out in Q4 have a very high probability of success. The analyst's base case assumes a four-plus letter gain in visual acuity compared to Lucentis monotherapy, resulting in 55%-60% share upside. His "homerun scenario," or five-plus letter, results in 150% share upside. He raised his price target for Ophthotech shares to $84 from $60.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/30/16
COWN
09/30/16
NO CHANGE
Target $60
COWN
Outperform
Ophthotech price target lowered to $60 from $80 at Cowen
Cowen analyst Tyler Van Buren said that Regeneron's (REGN) Phase 2 data for aflibercept co-formulated with rinucumab is negative for the class of anti-PDGFs as a whole and lowered his price target on Ophthotech (OPHT) to $60 from $80 after lowering his view of the probability of the success of its own wet AMD treatment to 50%. However, if a 3-4 letter benefit if observed when the Phase III trials read out in December, upside of $80-$120 per share from current levels is still possible, said Van Buren, who keeps an Outperform rating on Ophthotech shares.
REGN Regeneron
$402.82

0.8 (0.20%)

08/05/16
BARD
08/05/16
DOWNGRADE
Target $448
BARD
Neutral
Regeneron downgraded to Neutral at Baird
As reported previously, Baird downgraded Regeneron to Neutral from Outperform. The firm sees risk that the company will not be able to beat earnings consensus over the 2017/18 time frame unless there is a 15-20% downward revision in consensus estimates. Baird lowered its price target to $448 from $505 on Regeneron shares.
09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.

TODAY'S FREE FLY STORIES

CSGP

CoStar Group

$210.02

-1.35 (-0.64%)

17:24
02/22/17
02/22
17:24
02/22/17
17:24
Earnings
Breaking Earnings news story on CoStar Group »

CoStar Group sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 16

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

CSGP

CoStar Group

$210.02

-1.35 (-0.64%)

17:24
02/22/17
02/22
17:24
02/22/17
17:24
Hot Stocks
Breaking Hot Stocks news story on CoStar Group »

CoStar Group sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 16

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

CSGP

CoStar Group

$210.02

-1.35 (-0.64%)

17:22
02/22/17
02/22
17:22
02/22/17
17:22
Earnings
Breaking Earnings news story on CoStar Group »

CoStar Group sees Q1 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 16

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

IAG

IAMGold

$4.41

-0.05 (-1.12%)

17:20
02/22/17
02/22
17:20
02/22/17
17:20
Hot Stocks
Breaking Hot Stocks news story on IAMGold »

IAMGold sees 2017 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAG

IAMGold

$4.41

-0.05 (-1.12%)

17:19
02/22/17
02/22
17:19
02/22/17
17:19
Hot Stocks
Breaking Hot Stocks news story on IAMGold »

IAMGold sees 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAG

IAMGold

$4.41

-0.05 (-1.12%)

17:17
02/22/17
02/22
17:17
02/22/17
17:17
Earnings
IAMGold reports Q4 EPS 0c, consensus 0c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGG

Graco

$91.94

-0.18 (-0.20%)

17:17
02/22/17
02/22
17:17
02/22/17
17:17
Hot Stocks
Graco rebrands, redesigns Airlessco airless sprayer line »

Graco launched a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

DDC

Dominion Diamond

$9.21

-0.27 (-2.85%)

17:16
02/22/17
02/22
17:16
02/22/17
17:16
Hot Stocks
Dominion Diamond sees FY18 production 6.3M-7M carats »

During fiscal 2018, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$13.66

-0.68 (-4.74%)

17:15
02/22/17
02/22
17:15
02/22/17
17:15
Hot Stocks
Oasis Petroleum projects FY17 CapEx $605M »

Sees Fy17 production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 05

    Mar

OAS

Oasis Petroleum

$13.66

-0.68 (-4.74%)

17:14
02/22/17
02/22
17:14
02/22/17
17:14
Hot Stocks
Oasis Petroleum reports Q4 non-GAAP EPS (8c), consensus (12c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 05

    Mar

DDC

Dominion Diamond

$9.21

-0.27 (-2.85%)

17:13
02/22/17
02/22
17:13
02/22/17
17:13
Hot Stocks
Dominion Diamond reports Q4 diamond sales $129.9M »

During the fourth fiscal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$16.20

0.07 (0.43%)

17:13
02/22/17
02/22
17:13
02/22/17
17:13
Earnings
HP Inc. sees FY17 adjusted EPS $1.55-$1.65, consensus $1.59 »

Sees FY17 free cash flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 17

    Apr

CAKE

Cheesecake Factory

$60.10

-0.57 (-0.94%)

17:12
02/22/17
02/22
17:12
02/22/17
17:12
Earnings
Cheesecake Factory sees FY17 adjusted EPS $2.95-$3.07, consensus $3.05 »

Backs FY17 SSS growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 08

    Mar

CAKE

Cheesecake Factory

$60.10

-0.57 (-0.94%)

17:11
02/22/17
02/22
17:11
02/22/17
17:11
Earnings
Cheesecake Factory sees Q1 adjusted EPS 71c-74c, consensus 73c »

Sees Q1 SSS growth flat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 08

    Mar

IOC

InterOil

$48.36

-0.04 (-0.08%)

, XOM

Exxon Mobil

$80.93

-0.96 (-1.17%)

17:11
02/22/17
02/22
17:11
02/22/17
17:11
Hot Stocks
Exxon Mobil completes acquisition of InterOil »

InterOil (IOC) completed…

IOC

InterOil

$48.36

-0.04 (-0.08%)

XOM

Exxon Mobil

$80.93

-0.96 (-1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGR

Sturm, Ruger

$50.30

1 (2.03%)

17:09
02/22/17
02/22
17:09
02/22/17
17:09
Hot Stocks
Breaking Hot Stocks news story on Sturm, Ruger »

Sturm Ruger declares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

RGR

Sturm, Ruger

$50.30

1 (2.03%)

17:08
02/22/17
02/22
17:08
02/22/17
17:08
Earnings
Sturm Ruger reports Q4 EPS $1.10 vs. 88c last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

ALB

Albemarle

$92.44

-1.34 (-1.43%)

17:07
02/22/17
02/22
17:07
02/22/17
17:07
Hot Stocks
Albemarle and Tianqi terminate option for interest acquisition »

Albemarle and Tianqi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

LTC

LTC Properties

$47.13

0.24 (0.51%)

17:07
02/22/17
02/22
17:07
02/22/17
17:07
Earnings
LTC Properties reports Q4 FFO 78c vs. 74c last year »

Reports Q4 diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 01

    Mar

ERN

Erin Energy

$3.55

-0.1 (-2.74%)

17:05
02/22/17
02/22
17:05
02/22/17
17:05
Hot Stocks
Erin Energy CEO Segun Omidele resigns »

Erin Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip.com

$47.59

0.53 (1.13%)

17:04
02/22/17
02/22
17:04
02/22/17
17:04
Earnings
Ctrip.com reports Q4 non-GAAP EPS 32c, may not compare to consensus (3c) »

Reports Q4 revenue $730M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

OSIS

OSI Systems

$77.18

-0.51 (-0.66%)

17:04
02/22/17
02/22
17:04
02/22/17
17:04
Hot Stocks
OSI Systems sells German Healthcare unit for roughly EUR11.7M »

OSI Systems announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLX

TPG Specialty Lending

$19.41

-0.02 (-0.10%)

17:03
02/22/17
02/22
17:03
02/22/17
17:03
Hot Stocks
TPG Specialty Lending extends stock repurchase plan »

TPG Specialty Lending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

RMAX

RE/MAX Holdings

$60.45

0.05 (0.08%)

17:02
02/22/17
02/22
17:02
02/22/17
17:02
Hot Stocks
RE/MAX Holdings raises quarterly dividend 20% to 18c per share »

The quarterly dividend is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 09

    Mar

TSLX

TPG Specialty Lending

$19.41

-0.02 (-0.10%)

17:02
02/22/17
02/22
17:02
02/22/17
17:02
Earnings
TPG Specialty Lending reports Q4 NII 47c, consensus 44c »

Reports net asset value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.